An assessment of prevalence of Type 1 CFI rare variants in European AMD, and why lack of broader genetic data hinders development of new treatments and healthcare access.

MLA

Jones, Amy V., et al. “An Assessment of Prevalence of Type 1 CFI Rare Variants in European AMD, and Why Lack of Broader Genetic Data Hinders Development of New Treatments and Healthcare Access.” PLoS ONE, vol. 17, no. 9, Sept. 2022, pp. 1–22. EBSCOhost, https://doi.org/10.1371/journal.pone.0272260.

APA

Jones, A. V., Curtiss, D., Harris, C., Southerington, T., Hautalahti, M., Wihuri, P., Mäkelä, J., Kallionpää, R. E., Makkonen, E., Knopp, T., Mannermaa, A., Mäkinen, E., Moilanen, A.-M., Tezel, T. H., & Waheed, N. K. (2022). An assessment of prevalence of Type 1 CFI rare variants in European AMD, and why lack of broader genetic data hinders development of new treatments and healthcare access. PLoS ONE, 17(9), 1–22. https://doi.org/10.1371/journal.pone.0272260

Chicago

Jones, Amy V., Darin Curtiss, Claire Harris, Tom Southerington, Marco Hautalahti, Pauli Wihuri, Johanna Mäkelä, et al. 2022. “An Assessment of Prevalence of Type 1 CFI Rare Variants in European AMD, and Why Lack of Broader Genetic Data Hinders Development of New Treatments and Healthcare Access.” PLoS ONE 17 (9): 1–22. doi:10.1371/journal.pone.0272260.